Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, May 17, 2023
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
[ Wed, May 17th 2023
] - WOPRAI
Stephen Willey Maintained (XFOR) at Strong Buy with Increased Target to $5 on, May 17th, 2023
Stephen Willey of Stifel, Maintained "X4 Pharmaceuticals, Inc." (XFOR) at Strong Buy with Increased Target from $4 to $5 on, May 17th, 2023.
Stephen has made no other calls on XFOR in the last 4 months.
There are 4 other peers that have a rating on XFOR. Out of the 4 peers that are also analyzing XFOR, 0 agree with Stephen's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Stephen
- Swayampakula Ramakanth of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $3 on, Friday, May 5th, 2023
- Mayank Mamtani of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $3 on, Monday, April 10th, 2023
- Leland Gershell of "Oppenheimer" Maintained at Buy with Decreased Target to $4 on, Friday, March 24th, 2023
- Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy and Held Target at $3 on, Wednesday, March 22nd, 2023
